HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Doorn, P. A. Articles by Vermeulen, M. Search for Related Content PubMed PubMed Citation Articles by van Doorn, P. A. Articles by Vermeulen, M.

Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy

Inhibition in vitro and in vivo by IV immunoglobulin

Department of Neurology (Drs. van Doom and Vermeulen), Academic Hospital Dijkzigt, Rotterdam; and the Department of Immunohaematology and Bloodbank (Drs. van Doom and Brand), Academic Hospital Leiden, The Netherlands.

We tested serum from 48 patients with Guillain-Barré syndrome and 42 with chronic inflammatory demyelinating polyneuropathy (CIDP) against a selected neuroblastoma cell line (NBL 108cc15). Forty-two percent of the patients showed a positive immunofluorescence test against the NBL 108cc15. These antibodies were mainly of the IgM-class; they disappeared in all seven CIDP patients retested after improvement following intravenous IgG treatment (IV-IgG) and were present in only 5% of serum from patients with other disorders. Absorption studies showed a partial homology between the NBL 108cc15 and human sciatic nerve. In vitro studies showed that IgG from pooled normal donors (IV-IgG) inhibits the reaction between serum from a CIDP patient and the NBL cell line. This inhibition may be due to neutralization of autoantibodies against nervous tissue by anti-idiotypic antibodies in IV-IgG.

Address correspondence and reprint requests to Dr. van Doom, Department of Neurology, Academic Hospital Dijkzigt, Dr. Molewaterplein 40,3015 GD Rotterdam, The Netherlands.

Received February 26, 1988. Accepted for publication in final form April 11, 1988.

This article has been cited by other articles:

				M. Stangel, K. V. Toyka, and R. Gold Mechanisms of High-Dose Intravenous Immunoglobulins in Demyelinating Diseases Arch Neurol, June 1, 1999; 56(6): 661 - 663. [Abstract] [Full Text] [PDF]